In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Long-term predictive value of high sensitivity c-reactive protein for cancer mortality in patients undergoing percutaneous coronary intervention

Session Cardiovascular events in malignancies: from prediction to prevention

Speaker Hirohisa Endo

Congress : ESC Congress 2018

  • Topic : cardiovascular disease in special populations
  • Sub-topic : Cardio-Oncology
  • Session type : Rapid Fire Abstracts
  • FP Number : 6134

Authors : H Endo (Tokyo,JP), T Dohi (Tokyo,JP), K Miyauchi (Tokyo,JP), T Funamizu (Tokyo,JP), J Shitara (Tokyo,JP), H Wada (Tokyo,JP), S Doi (Tokyo,JP), H Iwata (Tokyo,JP), T Kasai (Tokyo,JP), S Okazaki (Tokyo,JP), K Isoda (Tokyo,JP), H Daida (Tokyo,JP)

Authors:
H. Endo1 , T. Dohi1 , K. Miyauchi1 , T. Funamizu1 , J. Shitara1 , H. Wada1 , S. Doi1 , H. Iwata1 , T. Kasai1 , S. Okazaki1 , K. Isoda1 , H. Daida1 , 1Juntendo University, Department of Cardiovasculer Medicine - Tokyo - Japan ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 1271

Background: Recent evidence suggests that anti-inflammatory therapy might reduce not only cardiovascular event but also occurrence of lung cancer. The relevance between the mortality due to cancer and high sensitivity C-reactive protein (hs-CRP) level remains unclear.

Purpose: We aimed to investigate the impact of hs-CRP level on long-term cancer mortality in patient with coronary artery disease.

Methods: This is a part of retrospective analysis of a single-center prospective percutaneous coronary intervention (PCI) registry (n=4589, enrolled from January 2000 to December 2016). In the present study, patients with the available data of baseline hs-CRP were analyzed (84.2%, n=3863). Patients were divided into two groups according to the median value of hs-CRP. We then evaluated the association between baseline hs-CRP level and both all-cause death and cancer death after PCI procedure.

Result: Of the entire cohort, mean age was 66.3±10.5 years and male gender was 82.5%. The median value of hs-CRP was 0.12 mg/dL (interquartile range (IQR): 0.05 to 0.37 mg/dL). The median follow-up period was 6.3 years (IQR: 2.6 to 6.3 years). There were 663 deaths (17.1%) including 228 (5.9%) cardiovascular deaths and 208 (5.3%) cancer deaths. In 208 cancer deaths, the proportion of gastrointestinal cancer was 43.9% (n=100) and lung cancer was 18.9% (n=43). Kaplan-Meier analysis revealed that higher hs-CRP group had a significantly higher incidence of both all-cause and cancer death (log-rank p<0.0001) (Figure 1). A multivariate Cox hazard model adjusted by clinical significant covariates showed higher hs-CRP level was significantly associated with higher risk of cancer death (hazard ratio: 2.13, 95% CI: 1.59–2.89, p<0.0001).

Conclusion: Elevated levels of baseline hs-CRP are associated with increased risk of cancer death in patients undergoing PCI. Hs-CRP measurement may be useful for identification of high-risk subgroups for anti-inflammatory interventions.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are